Beijing Immunochina Medical Science and Technology, also known as Yimiao Shenzhou, is a clinical-stage biopharmaceutical firm focusing on developing advanced medical treatments for hematologic cancers and solid tumors, with a key product candidate being IM19, a CAR-T cell therapy targeting CD19
Beijing Immunochina Medical Science and Technology, also known as Yimiao Shenzhou, is a clinical-stage biopharmaceutical firm focusing on developing advanced medical treatments for hematologic cancers and solid tumors, with a key product candidate being IM19, a CAR-T cell therapy targeting CD19.